Canada approves Pfizer COVID drug
TORONTO (AP) — Canada’s health regulator has approved a pill by Pfizer that treats the effects of COVID-19.
Health Canada authorized Paxlovid for adult patients with mild or moderate COVID-19 who are also at high risk of becoming more seriously ill. Health Canada did not authorize it for use on teenagers or on patients who are already hospitalized because of COVID-19.
The agency’s announcement Monday comes amid soaring numbers of infections because of the highly transmissible omicron variant.
Late last month, U.S. health regulators authorized the pill that patients will be able to take at home to ward off the worst effects of the virus. At the time, Pfizer said it had 180,000 treatment courses available worldwide, with roughly 60,000 to 70,000 allocated to the U.S. The company said it expected to have 250,000 available in the U.S. by the end of January.
Read more: https://apnews.com/article/coronavirus-pandemic-business-health-canada-1042136447a5822315cbe9d43d32563b
